Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $1.94 billion. The enterprise value is $1.97 billion.
| Market Cap | 1.94B |
| Enterprise Value | 1.97B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 151.04 million shares outstanding. The number of shares has increased by 30.82% in one year.
| Current Share Class | 151.04M |
| Shares Outstanding | 151.04M |
| Shares Change (YoY) | +30.82% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 10.94% |
| Owned by Institutions (%) | 82.71% |
| Float | 116.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 29.91 |
| PB Ratio | 159.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 24.30.
| Current Ratio | 4.73 |
| Quick Ratio | 4.28 |
| Debt / Equity | 24.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -799.46% and return on invested capital (ROIC) is -90.16%.
| Return on Equity (ROE) | -799.46% |
| Return on Assets (ROA) | -71.98% |
| Return on Invested Capital (ROIC) | -90.16% |
| Return on Capital Employed (ROCE) | -172.17% |
| Weighted Average Cost of Capital (WACC) | 18.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.14M |
| Employee Count | 274 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $1.24 million in taxes.
| Income Tax | 1.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.16% in the last 52 weeks. The beta is 3.17, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.17 |
| 52-Week Price Change | -13.16% |
| 50-Day Moving Average | 14.10 |
| 200-Day Moving Average | 12.04 |
| Relative Strength Index (RSI) | 42.85 |
| Average Volume (20 Days) | 2,960,719 |
Short Selling Information
The latest short interest is 20.45 million, so 13.54% of the outstanding shares have been sold short.
| Short Interest | 20.45M |
| Short Previous Month | 17.82M |
| Short % of Shares Out | 13.54% |
| Short % of Float | 17.54% |
| Short Ratio (days to cover) | 5.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -530.43M |
| Pretax Income | -585.61M |
| Net Income | -586.84M |
| EBITDA | -520.11M |
| EBIT | -530.43M |
| Earnings Per Share (EPS) | -$4.48 |
Balance Sheet
The company has $267.87 million in cash and $297.04 million in debt, with a net cash position of -$29.17 million or -$0.19 per share.
| Cash & Cash Equivalents | 267.87M |
| Total Debt | 297.04M |
| Net Cash | -29.17M |
| Net Cash Per Share | -$0.19 |
| Equity (Book Value) | 12.22M |
| Book Value Per Share | 0.08 |
| Working Capital | 233.90M |
Cash Flow
In the last 12 months, operating cash flow was -$511.40 million and capital expenditures -$475,000, giving a free cash flow of -$511.87 million.
| Operating Cash Flow | -511.40M |
| Capital Expenditures | -475,000 |
| Depreciation & Amortization | 10.32M |
| Net Borrowing | n/a |
| Free Cash Flow | -511.87M |
| FCF Per Share | -$3.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.82% |
| Shareholder Yield | -30.82% |
| Earnings Yield | -30.19% |
| FCF Yield | -26.33% |
Analyst Forecast
The average price target for Biohaven is $21.27, which is 65.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.27 |
| Price Target Difference | 65.27% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |